Engaging patients in healthy opioid prescriptions through community pharmacies
Healthy Opioid Prescription Engagement 2.0
This study is testing if a new program led by pharmacists can help adults who misuse opioids get better support and reduce their misuse compared to regular medication advice.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Utah Academic / other |
| Locations | 1 site (Salt Lake City, Utah) |
| Trial ID | NCT05141266 on ClinicalTrials.gov |
What this trial studies
This study is a randomized controlled trial conducted across 14 community pharmacies to evaluate the effectiveness of the Brief Intervention-Medication Therapy Management (BI-MTM) intervention in reducing opioid medication misuse. The trial will compare the pharmacist-led BI-MTM approach to standard medication counseling among adults who have screened positive for opioid misuse. Participants will be assessed at baseline, 2 months, and 6 months to measure changes in opioid misuse behaviors, with data linked to state prescription drug monitoring for objective outcomes. The study aims to leverage community pharmacies as a resource in addressing the opioid epidemic.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who speak English and have screened positive for opioid misuse.
Not a fit: Patients who are pregnant or those who cannot provide reliable contact information or access to their prescription monitoring data may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce opioid misuse and improve patient health outcomes in the community.
How similar studies have performed: Other studies have shown promise in utilizing community pharmacies for opioid misuse interventions, indicating a potential for success with this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 years) * English speaking * Not receiving cancer treatment * Who have a positive opioid misuse screen on the POMI will be eligible to learn about this study Exclusion Criteria: * Are pregnant (given potential pre/post-natal opioid use complications among pregnant women/offspring * Can-not provide collateral contact information for ≥2 contact persons (to ensure consistent contact/follow up) * Do not have a reliable land line or mobile phone to be contacted by study staff * Are filling only buprenorphine (given some formulations are not indicated for pain) * Plan to leave the area for an extended period of time in the next 6 months * Have had a psychotic and/or manic episode in the last 30 days (before consent, patients will be asked to screen for psychosis * Do not provide permission to access their state prescription drug monitoring data.
Where this trial is running
Salt Lake City, Utah
- University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Gerald Cochran, PhD — University of Utah
- Study coordinator: Gerald Cochran, PhD
- Email: jerry.cochran@hsc.utah.edu
- Phone: 801/213-0799
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.